The interrelationship of complement‐activation fragments and angiogenesis‐related factors in early pregnancy and their association with pre‐eclampsia

BJOG: An International Journal of Obstetrics and Gynaecology - Tập 117 Số 4 - Trang 456-462 - 2010
AM Lynch1, JR Murphy2, Gibbs Rs1, RJ Levine3, P.C.G. Giclas4, J E Salmon5, V. Michael Holers6
1Department of Obstetrics and Gynecology, University of Colorado Denver School of Medicine, Aurora, CO, USA
2National Jewish Health, Denver, CO, USA
3Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA
4Department of Pediatrics, Division of Allergy and Immunology, National Jewish Health, Denver, CO, USA
5Weill Cornell Medical Center, Hospital for Special Surgery, New York, NY, USA
6Division of Rheumatology, Departments of Medicine and Immunology, University of Colorado Denver School of Medicine, Aurora, CO, USA

Tóm tắt

Please cite this paper as: Lynch A, Murphy J, Gibbs R, Levine R, Giclas P, Salmon J, Holers V. The interrelationship of complement‐activation fragments and angiogenesis‐related factors in early pregnancy and their association with pre‐eclampsia. BJOG 2010; 117:456–462.

Objective  To determine the interrelationships during early pregnancy of complement‐activation fragments Bb, C3a and sC5b‐9, and angiogenesis‐related factors placental growth factor (PiGF), soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and soluble endoglin (sEng), and their associations with pre‐eclampsia.

Design  Prospective cohort study.

Setting  Denver complement study (June 2005–June 2008).

Population  A total of 668 pregnant women with singleton gestations, recruited between 10 and 15 weeks of gestation.

Methods  Using univariable and multivariable logistic regression analysis, concentrations of complement‐activation fragments and angiogenesis‐related factors were compared between 10 and 15 weeks of gestation in women who subsequently did or did not develop pre‐eclampsia. Interrelationships between these variables were tested using the non‐parametric Spearman rank correlation coefficient.

Main outcome measure  Pre‐eclampsia. The association of complement‐activation fragments and angiogenesis‐related factors with obesity was also examined.

Results  The mean (±SD) levels of complement Bb in early pregnancy among women who did and did not develop pre‐eclampsia were 0.84 (±0.26) μg/ml and 0.69 (±0.2) μg/ml, respectively (P = 0.001). Concentrations of PiGF were significantly (P = 0.01) lower (31 ± 12 pg/ml) in early pregnancy in the pre‐eclamptic group of women, as compared with the normotensive group (39 ± 32 pg/ml). The adjusted odds ratio (AOR) of Bb and PiGF were 2.1 (CI = 1.4–3.1, P < 0.0003) and 0.2 (CI = 0.07–0.7, P = 0.01), respectively. There was no significant difference in the levels of C3a, sC5b‐9, sFlt‐1 and sEng in early pregnancy among women who developed pre‐eclampsia, compared with women who remained normotensive during pregnancy. Higher levels of Bb (P = 0.0001) and C3a (P = 0.03), and lower levels of sFlt‐1 (P = 0.0002) and sEng (P = 0.0001) were found among women with obesity, compared with non‐obese controls. No meaningful relationships were found between the complement‐activation fragments and the angiogenesis‐related factors.

Conclusions  In this cohort during early pregnancy, increased concentrations of complement‐activation factor Bb and lower concentrations of PiGF were associated with the development of pre‐eclampsia later in pregnancy.

Từ khóa


Tài liệu tham khảo

10.1177/1933719107306232

10.1056/NEJMoa031884

10.1056/NEJMoa055352

10.1146/annurev.med.59.110106.214058

10.1016/j.jri.2007.03.015

10.1084/jem.20041783

10.1016/j.ajog.2007.10.793

10.1084/jem.200116116

10.1136/ard.61.suppl_2.ii46

Holers VM, 2004, Mol Immunol, 147

10.2353/ajpath.2007.070166

10.1056/NEJM200104053441406

10.1056/NEJM200104123441506

10.1016/S0960-9822(00)00476-0

10.1080/10641950701826711

10.1111/j.1600-065X.2008.00641.x

10.1016/j.it.2008.11.003

10.1084/jem.20061022

10.1016/j.ajog.2008.07.044

10.1016/j.ajog.2005.10.813

10.1016/S0140-6736(05)17987-2

10.1542/peds.37.3.403

10.1097/01.AOG.0000265804.09161.0d

10.1210/jc.2003-031244

10.1080/14767050701830480

10.1067/mob.2003.111

10.1067/mob.2001.113129

10.1161/HYPERTENSIONAHA.107.087700

10.1016/j.placenta.2007.12.010

10.1016/S0021-9258(18)42338-1

10.1152/ajpendo.00664.2006

10.1093/rheumatology/keg076

10.1016/j.molimm.2008.09.013

10.1210/jc.2008-1703

10.1038/ajh.2008.219

10.1016/j.ajog.2006.04.003

10.1016/j.ajog.2008.06.053